Results 81 to 90 of about 3,573 (200)

Pharmacokinetics and safety of erenumab in pediatric patients with migraine: A phase I, randomized, open‐label, multiple‐dose study

Clinical and Translational Science
Erenumab, a fully human monoclonal antibody targeting the calcitonin gene‐related peptide receptor, is efficacious and safe for prevention of attacks of migraine in adults.
Andrew D. Hershey, Gabriel Paiva da Silva Lima, Nicola Pannacciulli, Mia Mackowski, Reija Koukakis, Jennifer Williams McVige   +5 more
doaj   +1 more source

Early use of erenumab vs nonspecific oral migraine preventives: the APPRAISE randomized clinical trial [PDF]

Importance: Patients with migraine often cycle through multiple nonspecific preventive medications due to poor tolerability and/or inadequate efficacy leading to low adherence and increased disease burden. Objective: To compare the efficacy, tolerability,
Arkuszewski, Michal, Dolezil, David, Ferraris, Matias, Gil-Gouveia, Raquel, Lopez, Cristina Lopez, Maca, Jeff, Paemeleire, Koen, Pozo-Rosich, Patricia, Ritter, Shannon, Snellman, Josefin, Stepien, Adam, Stites, Tracy, Stude, Philipp   +12 more
core   +1 more source

Reduction of opioid and barbiturate use following initiation of rimegepant for migraine in the United States

Headache: The Journal of Head and Face Pain, Volume 66, Issue 4, Page 835-845, April 2026.
Abstract Objective The primary objective of this study was to evaluate opioid and barbiturate utilization before and after the first prescription of the calcitonin gene–related peptide receptor antagonist rimegepant in individuals with migraine. Background Although not recommended in migraine treatment guidelines, opioids and barbiturates are often ...
Noah Rosen, Aaron Jenkins, Karin Hygge Blakeman, Feng Dai, Lucy Abraham, Chelsea Leroue, Josh Brown   +6 more
wiley   +1 more source

The Bulletin: Sidney Kimmel Medical College at Thomas Jefferson University, Volume 67, Issue 1, Winter 2018 [PDF]

, 2018
This issue includes: Dean\u27s Column Findings: Living Electrodes may change neurological device design Ch-ch-ch-changes: Jefferson\u27s realignment of departments and programs The Difference Alumni Make: A message from Elizabeth Dale A Fighting ...

core   +1 more source

Effectiveness and tolerability of galcanezumab for migraine prevention in patients ≥65 years: A real‐life multicenter study

Headache: The Journal of Head and Face Pain, Volume 66, Issue 4, Page 939-949, April 2026.
Plain Language Summary This study shows that galcanezumab is equally effective and well‐tolerated in patients aged 65 and older as in younger patients, with a higher proportion of excellent responders in older patients. Despite having more baseline headache days, older patients responded well to the treatment, with age being linked to better outcomes ...
Julia Peris‐Subiza, Víctor Obach, Daniel Guisado‐Alonso, Fernando Velasco Juanes, Rocío Álvarez Escudero, María Martín Bujanda, Sonsoles Aranceta, Aintzine Ruisánchez, Natalia Roncero, Ane Mínguez‐Olaondo, Amaya Echeverria, Alba López‐Bravo, Ángel Luis Guerrero‐Peral, David García‐Azorín, Elisa Cuadrado‐Godia, Galca‐Only Study Group, Neus Fabregat, Marta Ruibal, Izaro Kortazar Zubizarreta, Nuria Riesco, Lucia González‐Fernández, Paula Manera, Agustín Oterino Duran, Yésica González‐Osorio, Santiago Fernández‐Fernández, Juan Carlos García‐Moncó, Isabel Fernández‐Pérez, Joan Jiménez‐Balado   +27 more
wiley   +1 more source

Reasons for patient reluctance to take preventive medications for migraine: Results of the OVERCOME (US) study

Headache: The Journal of Head and Face Pain, Volume 66, Issue 4, Page 846-858, April 2026.
Abstract Objectives/Background This study was undertaken to evaluate patient reasons for nonadoption of migraine‐preventive medications. Despite clear recommendations and eligibility criteria for migraine‐preventive treatment by the American Headache Society and the availability of these treatments, many people with migraine are not taking appropriate ...
Jessica Ailani, Rose Okonkwo, Elizabeth Johnston, Helen Hochstetler, Betzaida Martinez, Anthony Zagar, Robert A. Nicholson, Bert B. Vargas, E. Jolanda Muenzel, Richard B. Lipton   +9 more
wiley   +1 more source

Efficacy and safety of erenumab in the preventive treatment of migraine in adults: a systematic review

Chinese Journal of Contemporary Neurology and Neurosurgery, 2018
Objective To systematically evaluate the clinical efficacy and safety of erenumab in the preventive treatment of migraine in adults. Methods Taking Erenumab or AMG334 AND Migraine as search terms, retrieve in databases such as PubMed, Cochrane Library ...
Yan LIN, Deng CHEN, Da XU, Ling LIU
doaj   +1 more source

Surgical Interventions in Idiopathic Intracranial Hypertension—A Comprehensive Multi‐Center Study of Outcome and the Role of Treatment Indication

European Journal of Neurology, Volume 33, Issue 3, March 2026.
In this multicenter retrospective study of idiopathic intracranial hypertension, only 3.6% of patients required surgery, predominantly for acute visual deterioration. Both cerebrospinal fluid diversion and optic nerve sheath fenestration were effective in improving visual outcomes and resolving papilledema, while headache improvement was limited ...
Gabriel Bsteh, Nadja Skadkær Hansen, Sina Zaic, Steffen Hamann, Johanne Juhl Korsbæk, Nik Krajnc, Stefan Macher, Laleh Dehghani Molander, Klaus Novak, Therese Wallentin Steenfos, Marianne Wegener, Berthold Pemp, Rigmor Højland Jensen, Dagmar Beier, Kaare Fugleholm, Marianne Juhler, Karl Kirchner, Martin Michl, Christoph Mitsch, Nina Müller, Petersen Bibi Gronemann, Andreas Reitner, Christoph Stapf, Christian Wöber, Karin Zebenholzer   +24 more
wiley   +1 more source

Is erenumab an efficient alternative for the prevention of episodic and chronic migraine in Spain? Results of a cost-effectiveness analysis

The Journal of Headache and Pain
Background The reimbursement of erenumab in Spain and other European countries is currently restricted because of the cost of this novel therapy to patients with migraine who have experienced previous failures to traditional preventive treatments ...
Patricia Pozo-Rosich, José Luis Poveda, Carlos Crespo, María Martínez, José Manuel Rodríguez, Pablo Irimia   +5 more
doaj   +1 more source

Erenumab escalation in migraine - double dose without additional benefit : a retrospective experience [PDF]

Background: Erenumab is a monoclonal antibody specifically targeting the CGRP-receptor. Several studies showed efficacy and safety in patients with migraine. Less is known regarding dosage increase, especially in a difficult to treat patients. The aim
Burow, Philipp, Heintz, Simon, Kraya, Torsten, Maier, Patricia, Naegel, Steffen, Obermann, Mark, Stoessel, Grit, Storch, Peter   +7 more
core   +1 more source